Every S-3 that SiNtx Technologies, Inc. (SINT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow SINT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SINT filings page.
SINTX Technologies, Inc. is registering for resale up to 1,268,135 shares of common stock issuable upon exercise of new warrants held by a single selling stockholder under a June 29, 2026 letter agreement. These are secondary sales; the selling stockholder receives all proceeds from any share resales.
If the New Warrants are exercised for cash at $2.14 per share, SINTX could receive up to approximately $2.7 million, planned for working capital and general corporate purposes. Shares outstanding would rise from 6,664,534 to 7,932,669 if all New Warrants are exercised, in addition to a sizable existing warrant and preferred overhang.
The company highlights risks that warrant exercises and sales may pressure the stock price and increase dilution, and notes a Nasdaq notice received in May 2026 for not meeting the $2.5 million minimum stockholders’ equity requirement, with stockholders’ equity of $904,000. Failure to regain compliance could lead to delisting, reducing liquidity and potentially impairing future capital-raising.
SINTX Technologies, Inc. is registering the resale of 5,819,323 shares of common stock issued in a private placement on June 2, 2026. The shares include 1,882,846 Common Shares, 3,765,692 Warrant Shares (Class A, Class B and Placement Agent Warrant Shares), and 78,212 Compensation Shares.
The company will not receive proceeds from resales by the selling stockholders; however, if the registered Warrants are exercised for cash the company would receive up to approximately $8.3 million. Shares outstanding were 6,357,630 as of June 22, 2026, rising to 10,215,895 assuming exercise of all Warrants.
The prospectus discloses Nasdaq noncompliance: stockholders’ equity of $904,000 as reported for the quarter ended March 31, 2026, and a July 6, 2026 deadline to submit a plan to regain compliance.
SINTX Technologies (Nasdaq: SINT) filed a resale registration covering up to 1,741,539 shares of common stock to be offered by selling stockholders. The registered shares consist of 1,649,147 common warrant shares and 92,392 placement agent warrant shares issued in connection with a February 2025 private placement and an inducement letter dated September 8, 2025.
The company is not selling any shares in this prospectus and will not receive proceeds from selling stockholder resales. SINTX would receive up to approximately $8.3 million only if the warrants are exercised for cash; stated exercise prices include $4.79 for the common warrants and $4.3844 and $4.3125 for the placement agent warrants. Any cash received from exercises will be used for working capital and general corporate purposes.
Shares may be sold by the holders at market, fixed, related, or negotiated prices through various methods described in the plan of distribution. Shares outstanding were 3,683,989 as of October 20, 2025; this is a baseline figure, not the amount being registered. The last reported SINT price was $3.25 on October 22, 2025.
SINTX Technologies, Inc. is registering 541,450 shares of common stock for resale by a single selling stockholder under an S-3 prospectus. The shares include 216,450 PIPE Shares issued in a private placement and 325,000 Warrant Shares issuable upon exercise of common warrants.
SINTX will not sell any shares in this offering and will not receive proceeds from the stockholder’s resales. It could receive up to approximately $2.05 million only if all 325,000 warrants are exercised for cash at an exercise price of $6.30 per share. As of September 26, 2025, 3,585,856 shares of common stock were outstanding, rising to 3,910,856 shares if all these warrants are exercised.
The company develops advanced silicon nitride ceramics for biomedical and antipathogenic uses, including spinal implants and osteotomy wedges, and notes that investing in its securities involves a high degree of risk, including potential dilution and stock price pressure from warrant-related share sales.